At last check in pre-market trading, Progenity Inc. (PROG) shares were trading at $3.77, an increase of 11.54%. Last session, PROG stock closed at $3.38, increasing 14.19% or $0.42. PROG stock fluctuated between $2.97 and $3.48 throughout the day. In total, 139.66 million shares of PROG stock were exchanged, greater than the company’s 50-day daily volume of 64.87 million and greater than its Year-to-date volume of 16.8 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
During the past year, PROG stock has fallen -57.27%, and during the last week, it has risen 13.04%. A total of 7.30% has been gained by the PROG stock over the last six months, and a total of 39.67% over the last three months. This year, the stock has returned -36.35%. PROG stock rises following its debt reduction efforts.
What efforts has PROG made?
Progenity is a biotechnology organization improving in the fields of ladies’ wellbeing, gastrointestinal wellbeing, and oral biotherapeutics. PROG applies a multi-omics approach, joining genomics, epigenomics, proteomics, and metabolomics to its atomic testing items and to the advancement of a set-up of investigational ingestible gadgets intended to give exact analytic examining and medication conveyance arrangements.
PROG’s vision is to change medical services to turn out to be more exact and individual by further developing findings of infection and working on quiet results through limited therapy with designated treatments.
Progenity today declared that it has gone into privately negotiated agreements with specific non-associated holders of its current 7.25% convertible senior notes due 2025 (the “Notes”). PROG haggled to trade a total of $20,175,000 principal amount of Notes for a total of around 8,513,850 shares of its common stock.
The quantity of common stock shares for regard of the interest make-entire arrangements of the agreement includes the Notes issued. The trade exchanges are relied upon by PROG to close approximately October 26, 2021, dependent upon standard closing conditions. PROG won’t get any money continues from the trade exchanges.
The decrease in the debt accomplished by this trade exchange addresses around 38% of PROG’s non-associated obligation. Following the end of the trade exchanges, roughly $137,125,000 in total principal amount of Notes will stay remarkable, with terms unaltered, of which $103,500,000 is held by an associated holder, Athyrium Capital Management, LP.
What else PROG committed further?
Progenity (PROG) likewise consented to give a total of around 427,804 shares of common stock as “Waiver Shares” to specific financial backers in thought for a waiver of specific authoritative lock-up arrangements to which PROG concurred regarding earlier contributions of its protections. PROG won’t get any money continues from the issuance of the waiver shares.
